Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Inovio progresses on RRP treatment, faces trial challenges and opportunities

Inovio Pharmaceuticals is making progress on INO-3107 and other pipeline candidates while managing financials and strategic trial design.
The company faces challenges in trial design, patient representation, and regulatory requirements but sees opportunities in market access and patient outcomes.
Overall, Inovio remains focused on advancing DNA medicine and delivering on key objectives for the benefit of patients.
Analysts' questions and executive responses indicate a thorough approach to addressing concerns and ensuring trial success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

American Association for Cancer Research (AACR) Special Conference: Tumor Immunology and Immunotherapy : New immunology data showed ability of INO-3107 to induce an antigen-specific T cell response against HPV-6 and HPV-11 and drive recruitment of T cells into airway tissues and papilloma International Society of Vaccines Conference : Full safety and efficacy data from Phase 1/2 clinical study in patients with Recurrent Respiratory Papillomatosis (RRP) indicated that INO-3107 was well tolerated and immunogenic; 81% of patients in the trial required fewer surgeries post-treatment when compared to baseline PLYMOUTH MEETING, Pa. , Oct. 21, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the presentation of new data at scientific conferences for its lead candidate, INO-3107, for which the company is preparing a Biologics License Application for targeted submission in mid-2025 under the U.S. Food and Drug Administration's Accelerated Approval Pathway Program.

INOVIO Announces New Data at Scientific Conferences for Lead Candidate, INO-3107, as a Potential Treatment for RRP

Inovio (INO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Inovio (INO) Surges 6.8%: Is This an Indication of Further Gains?

PLYMOUTH MEETING, Pa. , Oct. 2, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made equity grants to certain employees under its 2022 Inducement Plan (the "Inducement Plan").

INOVIO Reports Inducement Grants Under Inducement Plan

PLYMOUTH MEETING, Pa. , Oct. 1, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conferences: AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy Poster by Dr. Matthew Morrow, VP of Translational Sciences at INOVIO Abstract Title: Reduction in Surgical Interventions for the Treatment of Recurrent Respiratory Papillomatosis by INO-3107 is Associated with Enriched Macrophage, Dendritic cell and T cell Signatures in Patient Airways Date and Time: October 19, 2024, 6:00 - 8:15pm ET Location: Boston, MA ISV Congress 2024 Oral presentation and poster by Dr. Michael Sumner, Chief Medical Officer at INOVIOAbstract Title: Clinical Assessment of Adjuvant Immunotherapy, INO-3107, in Adult Patients with Recurrent Respiratory Papillomatosis (RRP) Date and Time: October 22, 2024, 4:20pm KSTLocation: Seoul, Korea Fall Voice Poster by Dr. Jeffrey Skolnik, SVP of Clinical Development at INOVIOAbstract Title: Clinical Assessment of Adjuvant Immunotherapy, INO-3107, in Adult Patients with Recurrent Respiratory Papillomatosis (RRP) Date and Time: October 25 – October 26, 2024 Location: Phoenix, AZ World Vaccine Congress Europe Presentation and panel discussion by Dr. Dave Liebowitz, SVP Early-Stage Clinical Development at INOVIOTrack: Pre-Congress Workshop on Platform TechnologiesDate and Time: October 28, 2024, 10:00am CET Location: Barcelona, Spain Abstracts from these conferences will be made available on INOVIO's website following each presentation.

INOVIO to Present at Upcoming Scientific Conferences

PLYMOUTH MEETING, Pa. , Sept. 17, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conference: World Congress of Electroporation Oral Presentation by Trevor Smith, VP of Preclinical R&D at INOVIOAbstract Title: Development of in vivo-launched synthetic DNA-encoded antibodies employing CELLECTRA® electroporation technology Date and Time: September 18, 2024, 3:20pm – 3:35pm CET Location: Rome, Italy The abstract from the conference will be made available on INOVIO's website following the data presentation.

INOVIO to Present at Upcoming Scientific Conference

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Thomas Hong - Manager of Investor Relations Jacqueline Shea - President & Chief Executive Officer Steve Egge - Chief Commercial Officer Michael Sumner - Chief Medical Officer Peter Kies - Chief Financial Officer Conference Call Participants Anish Nikhanj - RBC Capital Markets Roy Buchanan - Citizens JMP Jay Olson - Oppenheimer Sudan Loganathan - Stephens Yi Chen - H.C. Wainwright Operator Good afternoon ladies and gentlemen and welcome to the Inovio Second Quarter 2024 Financial Results Conference Call.

Inovio Pharmaceuticals, Inc. (INO) Q2 2024 Earnings Call Transcript

PLYMOUTH MEETING, Pa. , Aug. 8, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the second quarter of 2024 and provided an update on recent company developments.

INOVIO Reports Second Quarter 2024 Financial Results and Recent Business Highlights

PLYMOUTH MEETING, Pa. , Aug. 1, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan").

INOVIO Reports Inducement Grant Under Inducement Plan

Data reviewed complies with standards that would be  used to evaluate an EU Marketing Authorization Application PLYMOUTH MEETING, Pa. , July 25, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that the European Medicines Agency's Committee for Advanced Therapies (CAT) has certified the quality and non-clinical data for INO-3107, INOVIO's lead candidate for the treatment of Recurrent Respiratory Papillomatosis (RRP).

Inovio Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107

PLYMOUTH MEETING, Pa. , July 25, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that second quarter 2024 financial results will be released after the market close on August 8, 2024.

INOVIO to Report Second Quarter 2024 Financial Results on August 8, 2024

Inovio (INO) soars 19% as its lead candidate, INO-3107, receives the innovative medicine tag under the U.K.'s Innovative Licensing and Access Pathway to treat recurrent respiratory papillomatosis.

Inovio (INO) Up as Lead Drug Gets Innovative Medicine Tag in UK

Inovio (INO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Inovio (INO) Soars 19.0%: Is Further Upside Left in the Stock?

Award recognizes the potential for INO-3107 to be the first therapeutic option in the United Kingdom for patients suffering from Recurrent Respiratory Papillomatosis (RRP) PLYMOUTH MEETING, Pa. , July 11, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that its lead DNA medicine candidate, INO-3107, has been designated an innovative medicine as part of the U.K.'s Innovative Licensing and Access Pathway (ILAP).

INO-3107 Awarded the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway

Mr. Egge brings over 25 years of biopharmaceutical experience building commercial organizations and successfully launching novel therapeutic products INOVIO poised to become a commercial-stage company with plans to submit a Biologics License Application for INO-3107 in second half of 2024 under U.S. Food and Drug Administration's Accelerated Approval Pathway PLYMOUTH MEETING, Pa. , July 2, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the appointment of Steven Egge as Chief Commercial Officer.

INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer

PLYMOUTH MEETING, Pa. , July 1, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced its inclusion in the Russell 2000® Index as part of the annual reconstitution of the Russell stock indexes.

INOVIO Added to Russell 2000® Index Effective July 1, 2024

PLYMOUTH MEETING, Pa. , June 4, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that INOVIO's President and CEO, Dr. Jacqueline Shea, and Chief Medical Officer, Dr. Michael Sumner will participate in a virtual fireside chat hosted by Sudan Loganathan, Ph.D.

INOVIO to Participate in Virtual Fireside Chat Hosted by Stephens Inc.

Novavax

Novavax just signed a lucrative agreement with a biotech giant. Inovio Pharmaceuticals is inching closer to launching its leading candidate.

Better Buy: Inovio Pharmaceuticals vs. Novavax

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) H.C. Wainwright 2nd Annual BioConnect Investor Conference Call May 20, 2024 12:30 PM ET Company Participants Jacqueline Shea - President & Chief Executive Officer Michael Sumner - Chief Medical Officer Unidentified Analyst Welcome to the H.C.

Inovio Pharmaceuticals, Inc. (INO) H.C. Wainwright 2nd Annual BioConnect Investor Conference (Transcript)

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) RBC Capital Markets Global Healthcare Conference May 15, 2024 10:00 AM ET Company Participants Jacqueline Shea - CEO Mike Sumner - Chief Medical Officer Conference Call Participants Gregory Renza - Biotechnology Equity Research Analyst, RBC Gregory Renza Let's get started and welcome back everyone to the 2024 RBC Global Health Care Conference. My name is Greg Renza, one of the Biotechnology Research Analyst here at RBC and we're pleased to be joined with Inovio Pharmaceuticals now.

Inovio Pharmaceuticals, Inc. (INO) Presents at 2024 RBC Capital Markets Global Healthcare Conference (Transcript)

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) The Citizens JMP Life Sciences Conference May 14, 2024 11:30 AM ET Company Participants Jacqueline Shea - CEO Conference Call Participants Roy Buchanan - Citizens JMP Roy Buchanan Everybody again for joining Citizens JMP Life Science Conference. My name's Roy Buchanan, I'm a biotech research analyst.

Inovio Pharmaceuticals, Inc. (INO) The Citizens JMP Life Sciences Conference (Transcript)

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q1 2024 Earnings Conference Call May 13, 2024 4:30 PM ET Company Participants Thomas Hong - Manager of Investor Relations Jacqueline Shea - President and Chief Executive Officer Michael Sumner - Chief Medical Officer Mark Twyman - Chief Commercial Officer Peter Kies - Chief Financial Officer Conference Call Participants Hartaj Singh - Oppenheimer Roy Buchanan - JMP Anish Nikhanj - RBC Capital Markets Roger Song - Jefferies Yi Chen - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the INOVIO First Quarter 2024 Financial Results Conference Call.

Inovio Pharmaceuticals, Inc. (INO) Q1 2024 Earnings Call Transcript

BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgical treatment for recurrent respiratory papillomatosis (RRP) Planning initiation of confirmatory trial for INO-3107 based on FDA feedback Advancing plans for Phase 3 trial of INO-3112 in combination with LOQTORZITM (toripalimab-tpzi) as a potential treatment for oropharyngeal squamous cell carcinoma (OPSCC) based on FDA feedback Balance sheet strengthened with underwritten offering of common stock and pre-funded warrants completed in April 2024 Cash runway projected into third quarter of 2025 PLYMOUTH MEETING, Pa. , May 13, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the first quarter of 2024 and provided an update on recent company developments.

INOVIO Reports First Quarter 2024 Financial Results and Recent Business Highlights

Inovio Pharmaceuticals' former two leading candidates both fell flat. The company is seeking approval for another product following positive clinical results.

This Under-the-Radar Stock Is Up by 96% This Year: Time to Buy?

PLYMOUTH MEETING, Pa. , April 29, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that management will participate in the following investor conferences during the month of May: The Citizens JMP Life Sciences Conference Date: Tuesday, May 14, 2024 Time: 11:30 AM ET Presenter: Dr. Jacqueline Shea, President & CEOFormat: Fireside Chat RBC Capital Markets 2024 Global Healthcare Conference Date: Wednesday, May 15, 2024 Time: 10:00 AM ET Presenter: Dr. Jacqueline Shea, President & CEOFormat: Fireside Chat H.C.

INOVIO to Participate in Upcoming Investor Conferences in May

PLYMOUTH MEETING, Pa. , April 29, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that first quarter 2024 financial results will be released after the market close on May 13, 2024.

News for Inovio Pharmaceuticals Stock (INO)